EUVIMEDScopri EUVIMED
Crossref

SherpaPak Cardiac Transport System: Experience in Pediatric Heart Transplantation

Anna Sather, Molly Marshall, Raghav Murthy, Jacqueline M Lamour, Christyn Chase, Neha Bansal iD

Clinical Transplantation · 2025-02 · 39 (2)

DOI: 10.1111/ctr.70095 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2025-01-30. Written by Anna Sather and 5 co-authors. Institution: Department of Environmental Medicine and Climate Science, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Major MEDLINE topics: Heart Transplantation, Heart Defects, Congenital, Organ Preservation, Tissue Donors. Cited 6 times so far (Crossref); 18 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

The present study aimed to assess the clinical outcomes of pediatric heart transplant patients whose donor hearts were preserved with the SherpaPakCardiac Transport System.

Methods

All pediatric patients undergoing heart transplantation at our center between January 2020 and June 2024 were included and described. Vasoactive inotropic score (VIS) was calculated. The cohort was divided into two groups by recipient diagnoses (cardiomyopathy vs. congenital heart disease [CHD]). They were compared based on demographics, operative details, and postoperative outcomes. The χ 2 and Fisher exact tests were used for categorical variables and the Mann–Whitney U test or t ‐test for continuous variables.

Results

A total of 18 patients were included. The median recipient age was 11.9 years (IQR: 2.5, 13.9). Half had cardiomyopathy, median total ischemic time was 236 min (IQR: 211.5, 283.5). Upon comparing the two groups, there were no significant differences observed in VIS or primary graft dysfunction (PGD) even though the median circulatory arrest time and bypass times were significantly longer in the CHD group ( p < 0.05). Three patients experienced early rejection (all with CHD), but there was no mortality.

Conclusions

The SherpaPak Cardiac Transport System provides safe outcomes for pediatric heart transplant patients, including those with complex CHD. Further multi‐institutional and registry studies are needed to evaluate this method for pediatric heart transplantation.

Subjects

MeSH terms (MEDLINE)

Heart TransplantationHeart Defects, CongenitalOrgan PreservationTissue DonorsGraft RejectionPostoperative ComplicationsCardiomyopathiesHumansChildFemaleMaleFollow-Up StudiesAdolescentPrognosisRetrospective StudiesChild, PreschoolGraft SurvivalRisk FactorsInfant

Author keywords

donors and donationheart (allograft) function/dysfunctionheart disease: congenital

Authors and institutions

  • Department of Environmental Medicine and Climate Science, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Division of Pediatric Cardiology, Mount Sinai Kravis Children's Hospital, New York, New York, USA.
  • Pediatric Cardiovascular Surgery, Mount Sinai Kravis Children's Hospital, New York, New York, USA.

ORCID profiles: Neha Bansal

Cite

APA

Sather, A., Marshall, M., Murthy, R., Lamour, J. M., Chase, C., & Bansal, N. (2025). SherpaPak Cardiac Transport System: Experience in Pediatric Heart Transplantation. Clinical Transplantation, 39(2). https://doi.org/10.1111/ctr.70095

Vancouver

Sather A, Marshall M, Murthy R, Lamour JM, Chase C, Bansal N. SherpaPak Cardiac Transport System: Experience in Pediatric Heart Transplantation. Clinical Transplantation. 2025;39(2). doi:10.1111/ctr.70095

BibTeX
@article{Sather2025,
  author = {Sather, Anna and Marshall, Molly and Murthy, Raghav and Lamour, Jacqueline M and Chase, Christyn and Bansal, Neha},
  title = {SherpaPak Cardiac Transport System: Experience in Pediatric Heart Transplantation},
  journal = {Clinical Transplantation},
  year = {2025},
  volume = {39},
  number = {2},
  doi = {10.1111/ctr.70095}
}
Start for free →